19th Nov 2026 11:21
(Alliance News) - GSK PLC on Thursday said its investigational targeted cancer drug Velzatinib has been granted orphan drug designation in Japan for the treatment of gastrointestinal stromal tumour.
The London-based pharmaceuticals firm said the approval by Japan's Ministry of Health Labour & Welfare was supported by data from the ongoing phase I/Ib StrateGIST 1 trial in advanced GIST, which showed promising anti-tumour activity and a promising tolerability profile.
In addition to the ODD in Japan, velzatinib has been granted US Food & Drug Administration fast-track designation, as well as US and European Union ODD.
GSK is accelerating the development of velzatinib, with phase III trials under way in first- and second-line advanced/metastatic GIST. Enrolment in the second-line clinical trial is tracking ahead of schedule, reflecting strong interest in velzatinib from the GIST community, with data expected in the second half of 2027, GSK said.
GSK traded down 1.2% at 1,836.00 pence each in London on Thursday.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline